These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 36298622)

  • 21. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-Vaccination Neutralization Responses to Omicron Sub-Variants.
    Jacobsen H; Katzmarzyk M; Higdon MM; Jiménez VC; Sitaras I; Bar-Zeev N; Knoll MD
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.
    Du Y; Chen L; Shi Y
    Hum Vaccin Immunother; 2022 Nov; 18(5):2062983. PubMed ID: 35499517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2.
    Jacobsen H; Sitaras I; Katzmarzyk M; Cobos Jiménez V; Naughton R; Higdon MM; Deloria Knoll M
    NPJ Vaccines; 2023 Oct; 8(1):159. PubMed ID: 37863890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
    Suntronwong N; Assawakosri S; Kanokudom S; Yorsaeng R; Auphimai C; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
    Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
    Chemaitelly H; Nagelkerke N; Ayoub HH; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36179099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.
    Tegally H; Moir M; Everatt J; Giovanetti M; Scheepers C; Wilkinson E; Subramoney K; Makatini Z; Moyo S; Amoako DG; Baxter C; Althaus CL; Anyaneji UJ; Kekana D; Viana R; Giandhari J; Lessells RJ; Maponga T; Maruapula D; Choga W; Matshaba M; Mbulawa MB; Msomi N; ; Naidoo Y; Pillay S; Sanko TJ; San JE; Scott L; Singh L; Magini NA; Smith-Lawrence P; Stevens W; Dor G; Tshiabuila D; Wolter N; Preiser W; Treurnicht FK; Venter M; Chiloane G; McIntyre C; O'Toole A; Ruis C; Peacock TP; Roemer C; Kosakovsky Pond SL; Williamson C; Pybus OG; Bhiman JN; Glass A; Martin DP; Jackson B; Rambaut A; Laguda-Akingba O; Gaseitsiwe S; von Gottberg A; de Oliveira T
    Nat Med; 2022 Sep; 28(9):1785-1790. PubMed ID: 35760080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant.
    Higdon MM; Baidya A; Walter KK; Patel MK; Issa H; Espié E; Feikin DR; Knoll MD
    Lancet Infect Dis; 2022 Aug; 22(8):1114-1116. PubMed ID: 35752196
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera.
    Jacobsen H; Sitaras I; Jurgensmeyer M; Mulders MN; Goldblatt D; Feikin DR; Bar-Zeev N; Higdon MM; Knoll MD
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.
    Kurhade C; Zou J; Xia H; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
    Nat Commun; 2022 Jun; 13(1):3602. PubMed ID: 35739094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covid-19: Omicron sub variants driving new wave of infections in UK.
    Wise J
    BMJ; 2022 Jun; 377():o1506. PubMed ID: 35724993
    [No Abstract]   [Full Text] [Related]  

  • 34. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
    Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman LS; Ash N; Alroy-Preis S; Huppert A; Milo R
    N Engl J Med; 2022 Jun; 386(23):2201-2212. PubMed ID: 35613036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents.
    Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
    EBioMedicine; 2022 Jun; 80():104066. PubMed ID: 35605428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
    Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation.
    Zhao Y; Zhao X; Zhang R; Ye B; Yuan X; Zhang D; Li L; Tian J; Guo Y; Gao GF; Liu WJ
    Lancet Reg Health West Pac; 2022 Apr; 21():100440. PubMed ID: 35350464
    [No Abstract]   [Full Text] [Related]  

  • 38. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.